New hope for tough blood cancers? early trial launches
NCT ID NCT07255898
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This early-phase study tests a new drug, BL-M24D1, in about 33 adults with multiple myeloma or other blood cancers that came back or didn't respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of working. Participants will be closely monitored for side effects and treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.